EN
  • FR
Contact
  • News
  • Media
  • Health professionals
  • CAREERS
LFB corp
  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
    • Governance
      • LFB SA Board of Directors
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
    • The LFB in pictures
  • Products and activities
    • Medicinal products
    • LFB Research Grant in Immunology
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
    • Transparency of interests for France
  • The LFB group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.

  • LFB Key dates

    Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.

  • LFB worldwide

    Worldwide, LFB has decided on a targeted strategy

  • A special place in France

    LFB has a special place in France, as a player in the healthcare industry with a public health mission

  • Governance

    A public company active in a competitive market

  • The LFB in pictures

    Discover a series of three videos looking back at the company's transformation over the last few years and unveiling its future objectives.

  • Medicinal products

    15 hospital-prescribed medicinal products

  • LFB Research Grant in Immunology

    LFB confirms its commitment to research for the benefit of patients by launching the second edition, "LFB Research Grant in Immunology."

  • Biosafety

    Patient safety, a top priority for LFB

  • Products under development

    There are several medicinal products at an advanced stage of development, for registration in Europe and the USA

  • Technology platforms

    Two proprietary platforms for therapeutic and technological innovation

  • Improving biosafety

    Innovations to constantly improve the biosafety of medicinal products

  • Rare diseases

    LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases

  • Relations with patients’ associations

    LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families

  • A responsible company

    LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities

  • Transparency of interests for France

    Transparency of interests for France

Medicinal products
marketed in
40 countries

burger

Home › The group › Governance

A limited company with predominantly
public share capital

The LFB Group, a French biopharmaceutical company, is a limited company
with predominantly public share capital, the French State
now being the sole shareholder.

Group Executive Committee

The LFB Group Executive Committee is chaired by Denis Delval, Chairman and CEO of LFB S.A.

Read more

LFB SA Board of Directors

Composition of the LFB SA Board of Directors, chaired by Denis DELVAL, chairman and CEO of LFB SA..

Read more

LFB BIOMEDICAMENTS

LFB BIOMEDICAMENTS, a subsidiary of LFB SA, specialises in plasma-derived medicinal products, is headed by Denis Delval.

Read more

LFB BIOTECHNOLOGIES

LFB BIOTECHNOLOGIES, a wholly-owned subsidiary of LFB SA, has its head office in Les Ulis (France).

Read more

Composition and tasks of the Committees

Composition and tasks of the Audit and Compensation committee and the strategy committee

Read more

Follow us on

  • The group
    • The LFB group
    • LFB Key dates
    • LFB worldwide
    • A special place in France
      • A player in the healthcare industry
      • A public health mission in france
    • Governance
      • Group Executive Committee
      • LFB BIOMEDICAMENTS
      • LFB BIOTECHNOLOGIES
      • Composition and tasks of the Committees
  • Products and activities
    • LFB Research Grant in Immunology 2021
    • Medicinal products
      • Immunology
      • Haemostasis
      • Intensive care
    • Biosafety
  • Innovation
    • Products under development
    • Technology platforms
      • EMABling®
      • rPRO™ technology
    • Improving biosafety
  • Responsibilities
    • Rare diseases
    • Relations with patients’ associations
    • A responsible company
      • Environmental responsibility
      • Social responsibility
      • Economic responsibility
    • Transparency of interests for France
  • Site map
  • Legal notices
  • Processing of personal data
  • Cookie management policy
  • Cookies management panel
  • Adverse effect reporting
 
 
 

 

×